PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Norris SL, McNally TK, Thakurta S. Drug Class Review: Quick-relief Medications for Asthma: Final Report Update 1 [Internet]. Portland (OR): Oregon Health & Science University; 2008 Oct.

Appendix D. Excluded studies

Reasons for exclusion:

1 = Foreign language

2 = Outcome not included

3 = Drug not included

4 = Population not included

5 = Wrong publication typea

6 = Wrong study designb

CitationExclusion Code
A levalbuterol metered-dose inhaler (Xopenex HFA) for asthma. Medical Letter on Drugs & Therapeutics. 2006 Mar 13 2006;48(1230):21–22.5
Aggarwal P, Pande JN, Guleria JS. Bronchodilators in acute bronchial asthma : a comparative study. Indian J Chest Dis Allied Sci. 1986;28(1):21–27.3
Agostini, M., G. Barlocco, et al. (1983). "Protective effect of fenoterol spray, ipratropium bromide plus fenoterol spray, and oral clenbuterol, on exercise induced asthma in children. Double blind controlled and randomized clinical trial." European Journal of Respiratory Diseases6
Ahlstrom H, Svenonius E, Svensson M. Treatment of asthma in pre-school children with inhalation of terbutaline in Turbuhaler compared with Nebuhaler. Allergy. 1989;44(7):515–518.6-DELIVERY
Albertini M, Pin I, Toussaint S, Fragneaud C. Efficacy of salmeterol versus alternative treatments in non-controlled asthmatic children. European Respiratory Society. 1999.5
Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J. Jul-Aug 2005;12(5):265–270.5
Ameredes BT. Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate: comment. Respirology. Nov 2004;9(4):570–571.5
American Lung Association Asthma Clinical Research, C., S. P.Peters, et al. (2007). "Randomized comparison of strategies for reducing treatment in mild persistent asthma." The New England Journal of Medicine 356(20): 2027–39.3
Andersen LH, Haghfelt T. Regional lung function in asthmatics in remission, before and after fenoterol. B Eur Physiopath Res. 1980;16(2):215–228.6-DESIGN
Anderson H, Ayres J, Sturdy P, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ. 2005;330:117–124.6
Anderson SD, Rozea PJ, Dolton R, Lindsay DA. Inhaled and oral bronchodilator therapy in exercise induced asthma. Aust N Z J Med. 1975;5(6):544–550.6
Angelici E, Delfino M, Carlone S, Serra P, Fineberg NS, Farber MO. Tolerance to inhaled fenoterol. Am Rev Respir Dis. Jun 1984;129(6):1014–1016.6-DESIGN
Ankerst J, Lotvall J, Cassidy S, Byrne N. Comparison of the bronchodilating effects of formoterol and albuterol delivered by hydrofluoroalkane pressurized metered-dose inhaler. Treat Respir Med. 2005;4(2):123–127.6-LONG VS. SHORT
Appleton S, Pilotto L, Smith B, Muhammad J. Anticholinergic bronchodilators versus beta2-adrenoceptor agonists for stable chronic obstructive pulmonary disease. Cochrane Db Syst Rev. 2006;1.5
Appleton S, Poole P, Smith B, Cates C, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Db Syst Rev. 2006;1.6
Appleton, S., T. Jones, et al. (2008). "Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease." Cochrane Database of Systematic Reviews.4
Aquilina R, Bergero F, Noceti P, et al. Protective effect of Duovent versus salbutamol in long-term treatment. Respiration. 1986;50(SUPPL. 2):240–244.6
Ariano R, Giacca S. Variations of individual susceptibility to beta-adrenergic and anticholinergic bronchodilator drugs. Minerva Pneumologie. 1981;20(3):141–147.1
Arledge TE, Liddle R, Stahl E, Rossing TH. Salmeterol does not cause tolerance during long-term asthma therapy. J Allergy Clin Immun. 1996;98(6 Pt 1):1116–1119.6-LONG VS. SHORT
Aronson N, Lefevre F, Piper M, et al. Management of chronic asthma. Evid Rep Technol Assess. Sep 2001(44):1–10.6-DESIGN
Arvidsson P, Larsson S, Lofdahl CG. Objective and subjective bronchodilation over 12 hours after inhaled formoterol: individual responses. J Asthma. 1993;30(6):459–465.6-LONG VS. SHORT
Arvidsson P, Larsson S, Lofdahl CG, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J. 1991;4(10):1168–1173.6-LONG VS. SHORT
Arvidsson P, Larsson S, Lofdahl CG, Melander B, Wahlander L, Svedmyr N. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J. 1989;2(4):325–330.6-LONG VS. SHORT
AstraZeneca (2006). "A comparison of the control of asthma inflammation provided by Symbicort turbuhaler 160/4.5 mcg/inhalation bid plus as-needed versus symbicort turbuhaler 320/9 μg/inhalation bid plus pulmicort turbuhaler 400μg/dose bid plus terbutaline turbuhaler 0.4mg/inhalation as-needed." ClinicalTrials.gov6
Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999;93(12):876–884.3
Auerbach D, Hill C, Baughman R, et al. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112(6):1514–1521.6
Avila-Castanon L, Casas-Becerra B, Del Rio-Navarro BE, Velazquez-Armenta Y, Sienra-Monge JJ. Formoterol vs. albuterol administered via Turbuhaler system in the emergency treatment of acute asthma in children. Allergol Immunopathol. 2004;32(1):18–20.6-LONG VS. SHORT
Ayers ML, Mejia R, Ward J, Lentine T, Mahler DA. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J. 2001;17(6):1132–1137.6
Bach-Mortensen N. Experience with the inhalation of Berotec powder in the treatment of asthma in children. Eur J Respir Dis. 1983;130:25–27.6
Backlund L, Fagerberg E. Ventilatory capacity after bronchodilatation with a new beta-sympathomimetic substance. Scand J Respir Dis. 1968;49(4):284–290.6-DESIGN
Bacon CJ. Nebulised salbutamol in treatment of acute asthma in children. Lancet. Jan 21 1978;1(8056):158.5
Bannister OM. The effectiveness of nebulised salbutamol in the management of acute asthma in children. Physiotherapy. May 1980;66(5):144–146.6
Barnabe R, Rossi M, Rottoli P. Fenoterol inhalation powder in long-term therapy of bronchial asthma. Eur J Respir Dis. 1983;128((Pt 2)):533–535.6-DESIGN
Barnes N. Bronchodilation subsensitivity to salbutamol after salmeterol. Lancet. Oct 7 1995;346(8980):968; author reply 968–969.5
Barnes, P. J. (2006). "Treatment with (R)-albuterol has no advantage over racemic albuterol." American Journal of Respiratory & Critical Care Medicine 174(9): 969–72; discussion 972–4.5
Barr RG, Rowe BH. Short acting beta2-agonists for exercise induced asthma. Cochrane Db Syst Rev. 2006;1.5
Bass BH, Disney ME, Morrison-Smith J. Effect of salbutamol on respiratory function in children with asthma. Lancet. Aug 23 1969;2(7617):438.5
Beach JR, Young CL, Harkawat R, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol. 1993;6(2):155–157.6-LONG VS. SHORT
Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immun. 1989;84(6 Pt 1):891–895.6-LONG VS. SHORT
Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma. Lung. 1990;168(Suppl):99–102.6-LONG VS. SHORT
Behling B, Matthys H. Comparison of efficacy and safety of formoterol with terbutaline in children with mild to moderate asthma. European Respiratory Society. 1999.5
Bell R, Sahay JN, Barber PV, Chatterjee SS, Cox G. A therapeutic comparison of ipratropium bromide and salbutamol in asthmatic patients. Curr Med Res Opin. 1982;8(4):242–246.6
Bellamy D, Penketh A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients. Postgrad Med J. 1987;63(740):459–461.6-SAMPLE SIZE
Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med. 2001;95(10):817–821.6-LONG VS. SHORT
Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax. 1994;49(8):771–774.6-LONG VS. SHORT
Bennis J, Svedmyr N. A controlled comparison of salbutamol and terbutaline inhaled by IPPV in asthmatic patients: a dose-response study. Scand J Respir Dis. 1977;101:113–117.6-SAMPLE SIZE
Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86(1):19–27.6-LONG VS. SHORT
Berger WE, Ames DE, Harrison D. A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Allergy Asthma Proc. Nov-Dec 2004;25(6):437–444.6-DESIGN
Berggren F, Ekstrom T. A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma. Respir Med. 2001;95(9):753–758.6-LONG VS. SHORT
Bethel RA, Sheppard D, Geffroy B, Tam E, Nadel JA, Boushey HA. Comparative effect between fenoterol, salbutamol and placebo by inhalatory way in asthmatic patients.: Effect of 0.25 ppm sulfur dioxide on airway resistance in freely breathing, heavily exercising, asthmatic subjects. Am Rev Respir Dis. 1985;131:659–661.3
Bianco S. Role of broxaterol in bronchial hyperresponsiveness. Respiration. 1989;55(Suppl 2):20–27.6
Bierman CW. Aerosolized metaproterenol in therapy of severe asthma. Chest. 1978;73(6 Suppl):1011–1012.6
Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36(5):391–398.6-DESIGN
Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Ann Allergy Asthma Immunol. 1999;82(2):205–211.6-LONG VS. SHORT
Bleecker E. Clinical reality: The safety and efficacy of the world's first CFC-free MDI. Eur Respir Rev. 1997;7(41):37–39.6-DESIGN
Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Chest. 1998;113(2):283–289.6-DELIVERY
Blokhin BM, Socolovsky AL, Bensch G, et al. Effect of regular use of inhaled formoterol in children with persistent asthma. European Respiratory Society. 1999.5
Bogaard JM, Slingerland R, Verbraak AF. Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics. Pharmatherapeutica. 1989;5(6):400–406.6-SAMPLE SIZE
Bolle R, Holt J. Inhalation treatment with fenoterol powder in childhood asthma. Tidsskr Nor Laegeforen. 1983;103(11):901–902+925.1
Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Resp Crit Care. 1994;149(4 Pt 1):935–939.6-LONG VS. SHORT
Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med. 2003;97(9):1067–1074.6-LONG VS. SHORT
Bosco AP, Rhem RG, Dolovich MB. In vitro estimations of in vivo jet nebulizer efficiency using actual and simulated tidal breathing patterns. J Aerosol Med. 2005;18(4):427–438.6-DESIGN
Boulet LP, Laviolette M, Boucher S, Knight A, Hebert J, Chapman KR. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. J Allergy Clin Immun. 1997;99(1 Pt 1):13–21.6-LONG VS. SHORT
Boulet, L. P., H. Turcotte, et al. (1989). "Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges." Journal of Allergy & Clinical Immunology 83(5): 882–7.6
Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration. 2005;72(Suppl 1):6–12.6
Boye NP, Kornstad S. A comparison of fenoterol powder capsules and fenoterol metered dose spray in bronchial asthma. Eur J Respir Dis. 1983;130:9–11.6-POWDER
Bracken MB, Triche EW, Belanger K, Saftlas A, Beckett WS, Leaderer BP. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol. 2003;102(4):739–752.6-DESIGN
Brambilla C, Le Gros V, Bourdeix I, Efficacy of Foradil in Asthma French Study G. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study. Clin Ther. 2003;25(7):2022–2036.6-LONG VS. SHORT
Bremner P, Burgess C, Beasley R, et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med. 1992;86(5):419–423.6-SAMPLE SIZE
Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J. 1993;6(2):204–210.4
Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J. 1992;5(9):1062–1067.6-LONG VS. SHORT
Bronsky E, Bucholtz GA, Busse WW, et al. Comparison of inhaled albuterol powder and aerosol in asthma. J Allergy Clin Immun. 1987;79(5):741–747.6-POWDER
Bronsky EA, Spector SL, Pearlman DS, Justus SE, Bishop AL. Albuterol aerosol versus albuterol Rotacapsregistered trade mark in exercise- iduced bronchospasm in children. J Asthma. 1995;32(3):207–214.6-POWDER
Brookman, L. J., L. J. Knowles, et al. (2007). "Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma." Current Medical Research & Opinion 23(12): 3113–22.3
Brown CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Db Syst Rev. 2006;1.6
Brown, C. D., D. McCrory, et al. (2008). "Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of ‘ chronic obstructive pulmonary disease." Cochrane Database of Systematic Reviews(1).4
Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399–404.6
Bundgaard, A., F. V. Rasmussen, et al. (1980). "Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets." Allergy 35(8): 639–45.6
Bundgaard A. Pretreatment of exercise-induced asthma with beta-2 agonists inhaled from RV to TLC or at TLC. A preliminary report. Eur J Respir Dis. 1983;128((Pt 2)):518–520.6-DESIGN
Bundgaard A, Buch D, Schmidt A, Bach-Mortensen N. Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder. Eur J Respir Dis. 1983;64(Suppl 30):36–41.6
Bundgaard A, Schmidt A. Double-blind pretreatment of exercise-induced asthma with sequential inhalations of fenoterol from an aerosol and as a powder (second of two parts). Eur J Respir Dis. 1983;130:66–72.6-POWDER
Bundgaard A, Schmidt A. Pretreatment of exercise-induced asthma by fenoterol delivered as inhalation powder and pressurized aerosol. Ann Allergy. 1982;48(1):36–39.6-POWDER
Busse W, Levine B, Andriano K, Lavecchia C, Yegen U. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Clin Ther. 2004;26(10):1587–1598.6-LONG VS. SHORT
Busse WW, Bush RK. Comparison of Uniphyl tablets and inhaled albuterol as maintenance therapy in asthmatic adults. Am J Med. 1988;85(1 B):10.5
Camargo, C. A., Jr., C. H. Spooner, et al. (2008). "Continuous versus intermittent beta-agonists for acute asthma." Cochrane Database of Systematic Reviews(1).6
Camargo CA, Jr., Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists for acute asthma. Cochrane Db Syst Rev. 2006;1.6-DELIVERY
Carroll, C. (2006). "Trial of terbutaline for the treatment of status asthmaticus in children."
Carson JW, Taylor MR. Relapse after single dose nebulised salbutamol in children with acute asthma. Ir Med J. Apr 1985;78(4):93–96.6-DESIGN
Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Brit Med J Clin Res Ed. 1993;306(6884):1034–1037.6-LONG VS. SHORT
Cazzola M, Califano C, Di Perna F, et al. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Respir Med. 2002;96(10):790–795.6-LONG VS. SHORT
Cazzola M, Centanni S, Regorda C, et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther. 2001;14(1):41–45.6
Cazzola M, D'Amato M, Califano C, et al. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther. 2002;24(4):595–604.6-LONG VS. SHORT
Centre for Reviews and, D. (2008). "Bronchodilator delivery in acute airflow obstruction: a meta-analysis (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Centre for Reviews and, D. (2008). "Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Centre for Reviews and, D. (2008). "Continuous vs intermittent \ beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Centre for Reviews and, D. (2008). "Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Centre for Reviews and, D. (2008). "A meta-analysis of the effects of ipratropium bromide in adults with acute asthma (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Centre for Reviews and, D. (2008). "Review of therapeutically equivalent alternatives to short acting beta 2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Centre for Reviews and, D. (2008). "The role of ipratropium bromide in the emergency management of acute asthma exacerbation; a metaanalysis of randomized clinical trials (Structured abstract)." Database of Abstracts of Reviews of Effects.6
Chambers S, Dunbar J, Taylor B. Inhaled powder compared with aerosol administration of fenoterol in asthmatic children. Arch Dis Child. 1980;55(1):73–74.6-POWDER
Charoenpan P, Kiatboonsri S, Uswanopakhun P, Vongvivat K, Sulaimanee P. The effects of inhaled ipratropium bromide, fenoterol and their combination in COPD patients. J Med Assoc Thai. 1990;73(2):91–95.6
Chavasse, R., P. Seddon, et al. (2008). "Short acting beta2-agonists for recurrent wheeze in children under two years of age [Systematic Review]." Cochrane Database of Systematic Reviews.6
Chavasse R, Seddon P, Bara A, McKean M. Short acting beta2-agonists for recurrent wheeze in children under two years of age. Cochrane Db Syst Rev. 2006;1.6
Chervinsky P. A comparative evaluation of fenoterol and terbutaline in the treatment of asthma. Ann Allergy. 1978;40(3):189–194.3
Chervinsky P. The development of drug tolerance during long-term beta2-agonist bronchodilator therapy. Chest. 1978;73(6 Suppl):1001–1002.3
Chervinsky P. Letter: Beta-2-receptor agonists in treatment of asthma. N Engl J Med. Sep 11 1975;293(11):559–560.5
Chervinsky P. Clinical evaluation of fenoterol aerosol in asthma. Ann Allergy. 1977;39(3):179–183.6
Chhabra SK. Differing bioavailability of salbutamol metered-dose inhalers. J Asthma. 1987;24(4):215–218.6-DELIVERY
Chhabra SK. Comparison of salbutamol dry powder aerosol with pressurised aerosol. Indian J Chest Dis Allied Sci. Oct-Dec 1993;35(4):163–166.6-POWDER
Choo-Kang YF, Tribe AE, Grant IW. Salbutamol by intermittent positive pressure ventilation in status asthmaticus. Scott Med J. Jul 1974;19(4):191–195.6-DESIGN
Chorley BN, Li Y, Fang S, Park J-A, Adler KB. (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. American Journal of Respiratory Cell & Molecular Biology. Jan 2006;34(1):119–127.6
Chowdhury BA. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma. J Allergy Clin Immun. 2002;110(2):324; author reply 325–328.5
Chuchalin A, Kasl M, Bengtsson T, Nihlen U, Rosenborg J. Formoterol used as needed in patients with intermittent or mild persistent asthma. Respir Med. 2005;99(4):461–470.6-LONG VS. SHORT
Chuchalin AG, Manjra AI, Rozinova NN, et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. J Aerosol Med. 2005;18(1):63–73.6-POWDER
Clauzel AM. Characteristics of bronchodilating activity of formoterol. Lung. 1990;168 Suppl:71–75.6-LONG VS. SHORT
Cloosterman SG, Bijl-Hofland ID, van Herwaarden CL, et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest. 2001;119(5):1306–1315.6-LONG VS. SHORT
Cochrane GM, Clark TJ, Hanan ME. The role of oral bronchodilator therapy as shown by a comparison between salbutamol and terbutaline. Curr Med Res Opin. 1973;1(9):517–523.3
Cockcroft DW, Davis BE, Swystun VA, Marciniuk DD. Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immun. 1999;103(6):1049–1053.4
Coleman ME, Howard LA. Controlled trial of metaproterenol aerosol inbronchial asthma. Ann Allergy. 1965;23(9):434–436.6
Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med. 1996;100(1A):11S-18S.6
Condie R. Double-blind trial of an anti-asthmatic preparation in general practice. Practitioner. 1968;201(206):924–929.3
Connellan SJ, Wilson RS. Nebulised salbutamol in adult asthma. Lancet. Mar 25 1978;1(8065):662–663.5
Connellan SJ, Wilson RS. The use of domiciliary nebulised salbutamol in the treatment of severe emphysema. Br J Clin Pract. May 1979;33(5):135–136.6-DESIGN
Conoscenti C. A single dose, randomized, double-blind, crossover comparison of Combivent(R) MDI and albuterol HFA MDI in patients with moderate to severe persistent asthma and persistent symptoms despite treatment with inhaled corticosteroids. ClinicalTrialsgov. 2005.5
Conway PH, Edwards S, Stucky ER, Chiang VW, Ottolini MC, Landrigan CP. Variations in management of common inpatient pediatric illnesses: hospitalists and community pediatricians. Pediatrics. Aug 2006;118(2):441–447.4
Cook JJ, Fergusson DM, Dawson KP. Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica. 1985;4(6):383–386.6
Costello JF, Honeybourne D. Nebulised salbutamol in life-threatening asthma. Br Med J. 1979;1(6173):1284–1285.5
Crompton GK, Grant IW. Pirbuterol. Lancet. 1984;1(8380):795.5
Crompton GK, Wallert B, Bengtsson T, Soliman S. Long acting beta-2 agonists: a meta analysis of oral bambuterol and inhaled salmeterol in nocturnal asthma. European Respiratory Society. 1999.5
Croner S, Hedenskog S, Kjellman NI, Odelram H. Salbutamol by powder or spray inhalation in childhood asthma. Allergy. 1980;35(7):589–592.6-POWDER
Cueva Velazquez J, Salazar Mallen M, Celis A, Cicero R. Effect of salbutamol on lung volumes in bronchial asthma. Postgrad Med J. Mar 1971;47:Suppl:100–105.6-DESIGN
Currie GP, Jackson CM, Ogston SA, Lipworth BJ. Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. Q J Med. 2003;96(6):435–440.6
Da Costa JL, Goh BK, Teoh PC. Studies of new sympathomimetic beta-receptor stimulating drugs in asthmatic patients. IV Acomparative trial of subcutaneous terbutaline (Bricanyl) and salbutamol (Ventolin). Singapore Med J. 1976;17(1):7–9.3
Dahl R, Creemers JP, Van Noord J, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration. 2004;71(2):126–133.6-DELIVERY
Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Resp Crit Care. 2001;164(5):778–784.6
Dakhil J, Clauzel AM, Michel FB. Effect of SCH 1000 on bronchial hyperreactivity compared to that of fenoterol. Respiration. 1984;46(4):370–378.1
D'Alonzo G. Efficacy of inhaled salmeterol in the treatment of asthma. Eur Respir Rev. 1995;5(27):128–132.6-LONG VS. SHORT
D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. J Amer Med Assoc. 1994;271(18):1412–1416.6-LONG VS. SHORT
D'Amato G, Schiano M, Balzano G, Cocco G, Melillo G. Evaluation of protective effect of fenoterol in allergen-induced bronchospasm. Allergy. 1983;38(1):19–24.6
D'Amato G, Schiano M, Balzano G, Cocco G, Melillo G. Preventive effect of fenoterol on allergen-induced bronchospasm. Eur J Respir Dis. 1983;128(Pt 2):509–512.6
D'Amato G, Schiano M, Cocco G, Melillo G. Double-blind crossover study on the protective effect of fenoterol - administered by pressurized aerosol and in powder form - in allergen-induced asthma. Respiration. 1984;45(3):276–280.6-POWDER
Datta D, Lahiri B, ZuWallack R. A randomised double-blind placebo controlled study comparing single doses of nebulised levalbuterol, albuterol and combined ipratropium-albuterol in stable COPD. Chest. 2002(SUPPL).5
Datta D, Lahiri B, ZuWallack R. A comparison of nebulized levalbuterol, albuterol, and combined albuterol and ipratropium in patients with stable COPD: preliminary observations. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2002;20(Suppl 38):246s.5
Daugbjerg P, Nielsen KG, Skov M, Bisgaard H. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children. Acta Paediatr. 1996;1992) 85(6):684–687.6-LONG VS. SHORT
Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med. 1998;92(2):256–263.6
De Carli G, Arpinelli F, Irvine SH, Bamfi F, Ravinetto R, Recchia G. Change of quality of life induced by salmeterol and salbutamol in adult asthmatic patients. Therapie. 1995;50(Suppl):118.5
Del Rio-Navarro B, Gazca-Aguilar A, Quibrera Matienzo JA, Rodriguez Galvan Y, Sienra-Monge JJ. Metabolic and electrocardiographic effects of albuterol in pediatric asthmatic patients treated in an emergency room setting. Allergol Immunopathol. Jan-Feb 1999;27(1):18–23.6-DESIGN
Deloughery M, Gilmore D. Open assessment of fenoterol (Berotec). Med J Aust. Apr 21 1979;1(8):341.5
Dente FL, Del Bono L, Del Bono N. Cold-air isocapnic hyperventilation test in the study of the effects and duration of action of Duovent. Comparison with fenoterol, salbutamol, disodium cromoglycate and placebo. Respiration. 1986;50(2):196–200.6
Di Lorenzo G, Morici G, Norrito F, et al. Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Clin Exp Allergy. 1995;25(10):951–956.6-LONG VS. SHORT
Dinda P, Bernstein A, Chatterjee SS. A new bronchodilator: terbutaline. Br J Clin Pract. 1971;25(7):323–325.3
Dirksen H, Groth S. Fenoterol inhalation powder as an alternative to treatment with the metered dose inhaler. Eur J Respir Dis. 1983;130:48–53.6-POWDER
Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Ann Allergy Asthma Immunol. 1997;79(1):85–88.6-DELIVERY
Donohue JF, Parsey M, Andrews C, Group TLCS. Evaluation of the efficacy and safewty of levalbuterol in subjects with COPD. COPD: J Chronic Obstructive Pulm Dis. 2006;3(3):125–132.4
Dougherty JA, Didur BL, Aboussouan LS. Long-acting inhaled beta 2- agonists for stable COPD. Ann Pharmacother. Sep 2003;37(9):1247–1255.5
Duane M, Chandran L, Morelli PJ. Recurrent supraventricular tachycardia as a complication of nebulized albuterol treatment. Clin Pediatr. Nov 2000;39(11):673–677.5
Dubois EF, Roder E, Ifle RG. Bronchodilating effects of cumulative doses of formoterol from a novel multi-dose inhaler (Airmax). Respir Med. 2003;97(1):71–74.6-DELIVERY
D'Urzo AD. Long-acting beta 2-agonists. Role in primary care asthma treatment. Can Fam Physician. Oct 1997;43:1773–1777.5
D’Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3- week, randomized, double-blind, within-patient, multicenter study. Chest. 2001;119(5):1347–1356.6-LONG VS. SHORT
Dusser D, Vicaut E, Lefrancois G, Formoterol HFAg. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Respiration. 2005;72(Suppl 1):20–27.6-POWDER
Ekstrom T, Ringdal N, Sobradillo V, Runnerstrom E, Soliman S. Low- dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respir Med. 1998;92(8):1040–1045.6-LONG VS. SHORT
Ekstrom T, Ringdal N, Tukiainen P, Runnerstrom E, Soliman S. A 3- month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study. Ann Allergy Asthma Immunol. 1998;81(3):225–230.6-LONG VS. SHORT
Elgefors B, Wilhelmsen L. Effects of a new stimulator of beta-receptors, terbutaline, on ventilatory capacity, lung resistance, heart rate and blood pressure. Eur J Clin Pharmacol. Sep 1971;3(4):209–214.6-DOSAGE
Eliraz A, Ramirez-Rivera A, Ferranti P, et al. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling. Int J Clin Prac. 2001;55(3):164–170.6-DELIVERY
Ence TJ, Tashkin DP, Ho D, Child JS. Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol. Ann Allergy. 1979;43(4):229–236.3
Everard, M. L., A. Bara, et al. (2008). “Anticholinergic drugs for wheeze in children under the age of two years [Systematic Review].” Cochrane Database of Systematic Reviews.6
Faurschou P, Steffensen I, Jacques L. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Eur Respir J. 1996;9(9):1885–1890.6-LONG VS. SHORT
Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest. 2003;123(6):1817–1824.6
Filiz A, Ekinci E, Dikensoy O, Bulgur D, Oz M. Comparison of a single dose of aerosol salbutamol and fenoterol/ipratropium on bronchial asthmatic patients. Del Med J. 1994;66(10):549–552.6
Fitoussi S, Dobson C, Ayre G, Langholff W. Saftey and tolerability profile of high dose formoterol (Aerolizer(R)) and salbutamol (MDI) given for three days in patients with mild persistent asthma. Chest. 2002.5
FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther. 2005;27(4):393–406.3
FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immun. 1999;103(3 Pt 1):427–435.6-LONG VS. SHORT
Fitzpatrick MF, Mackay T, Driver H, Douglas NJ. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. Brit Med J Clin Res Ed. 1990;301(6765):1365–1368.6
Formgren H. Broncho-and cardioselective beta-receptor active drugs in the treatment of asthmatic patients. Clinical studies of effects and side effects of terbutaline, practolol and metoprolol. Scand J Respir Dis. 1977;97:1–37.4
Formgren H. Clinical comparison of inhaled terbutaline and orciprenaline in asthmatic patients. Scand J Respir Dis. 1970;51(3):203–211.4
Formgren H. Experiences of longterm treatment of asthma with terbutaline. A study on frequency of side effects and therapeutic effect. Acta Allergol. Apr 1971;26(2):81–89.6-DESIGN
Formgren H, Sjokvist A, Stahl E, Wiren JE. Terbutaline in COPD comparison between Turbuhaler (R) and chlorofluorocarbon (CFC) inhaler. Lung. 1994;172(5):271–280.6-POWDER
Foucard T, Lonnerholm G. A study with cumulative doses of formoterol and salbutamol in children with asthma. Eur Respir J. 1991;4(10):1174– 1177.6-LONG VS. SHORT
Freedman BJ. Trial of new bronchodilator, terbutaline, in asthma. Br Med J. 1971;1(750):633–636.3
Frey U, Brodbeck T, Majumdar A, et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature. Dec 1 2005;438(7068):667–670.5
Fuglsang G, Pedersen S. Comparison of a new multidose powder inhaler with a pressurized aerosol in children with asthma. Pediatr Pulmonol. 1989;7(2):112–115.6-POWDER
Fuller R. Safety of salmeterol in the treatment of asthma. Eur Respir Rev. 1995;5(27):133–137.5
Galant SP, Groncy CE, Duriseti S, Strick L. The effect of metaproterenol in chronic asthmatic children receiving therapeutic doses of theophylline. J Allergy Clin Immun. 1978;61(2):73–79.6
Garrett JE, Turner P. The severity of asthma in relation to beta agonist prescribing. N Z Med J. Feb 13 1991;104(905):39–40.6-DESIGN
Gawchik S, Noonan M, Saccar C, et al. A dose-ranging trial of nebulized (R)-albuterol (Levalbuterol) with racemic albuterol in pediatric patients with asthma. Ann Allergy Asthma Immunol. 1998;80:87.5
Gayrard P, Orehek J, Charpin J. Comparative study of a new beta- adrenergic stimulant in asthma: salbutamol. Postgrad Med J. Mar 1971;47:Suppl:46–50.6
Gent PN, Hughes DT, Nisbet IG, Pearson SB, Sturgeon JG. Double- blind comparative trial of two metered bronchodilator aerosols. Br J Clin Pract. 1968;22(11):479–481.5
Geoffroy P, Lalonde RL, Ahrens R, et al. Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. Ann Allergy Asthma Immunol. 1999;82(4):377–382.6-POWDER
Geumei AM, Miller WF, Miller J, Gast LR. Bronchodilator effect of a new oral beta adrenoreceptor stimulant, Th1165a. A comparison with metaproterenol sulfate. Chest. 1976;70(4):460–465.3
Gibson GJ, Greenacre JK, Konig P, Conolly ME, Pride NB. Use of exercise challenge to investigate possible tolerance to beta- adrenoceptor stimulation in asthma. Brit J Dis Chest. Jul 1978;72(3):199–206.6
Gilmartin JJ, Veale D, Murray A, Adams PC, Gibson GJ. Cardiac effects of salbutamol given by air driven nebuliser at home. Thorax. Apr 1986;41(4):331–332.6
GlaxoSmithKline. Study of asthma and genetics. ClinicalTrialsgov. 2005.5
GlaxoSmithKline. Study of asthma in patients of african descent. ClinicalTrialsgov. 2005.5
GlaxoSmithKline. The salmeterol multicenter asthma research trial (SMART).5
Glendining S. The use of Fenoterol (Berotec) respirator solution 0.5% in patients with severe asthma. New Zealand Journal Physiotherapy. 1979;7(2, November):26–28.6-DOSAGE
Gluck JC, Gluck PA. Asthma controller therapy during pregnancy. Am J Obstet Gynecol. Feb 2005;192(2):369–380.6-DESIGN
Goldgraber MB. Terbutaline: an effective bronchodilator by inhalation. Ann Allergy. 1977;38(2):127–128.6
Goldkorn A, Diotto P, Burgess C, et al. The pulmonary and extra- pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 2004;9(1):102–108.6-LONG VS. SHORT
Gongora HC, Wisniewski AF, Tattersfield AE. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Am Rev Respir Dis. 1991;144(3 Pt 1):626–629.6-LONG VS. SHORT
Graff-Lonnevig V, Browaldh L. Twelve hours’ bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clin Exp Allergy. 1990;20(4):429–432.6-LONG VS. SHORT
Groggins RC, Milner AD, Stokes GM. Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma. Arch Dis Child. 1981;56(5):342–344.6
Gronnerod TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med. 2000;94(7):661–667.6-LONG VS. SHORT
Gross NJ, Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent. Am Rev Respir Dis. 1987;136(5):1091–1094.6
Grossman J, Geoffroy P, Hill MR, Vaughan LM, Nichols K. Comparison of efficacy and safety of single and double doses of albuterol sulfate via Spiros? dry powder inhaler (DPI) and albuterol via Ventolin(R) metered dose inhaler (MDI) in asthmatics. Ann Allergy Asthma Immunol. 1998;80(127).5
Gunawardena KA, Clay MM, Jenkins MM. The Diskus/Accuhaler multi- dose powder inhaler for the delivery of salmeterol in adult asthmatics. British Journal of Clinical Research. 1995;6:57–61.6-DELIVERY
Gunawardena KA, Saunders EFS, Buck HB. Comparison of the bronchodilator response to salbutamol delivered by the Clickhaler and by Ventodisk. Journal of Drug Assessment. 1999;2:165–172.6-POWDER
Gupta PR, Purohit SD, Saxena A, Bhatnagar M. A comparison of efficacy and patient compliance between inhaled aerosol and powder forms of salbutamol in asthma. Lung India. 1991;9:18–21.6-POWDER
Gupta SC, Mathur RN, Swaroop AK, Goyal RK. Metabolic effects of salbutamol in bronchial asthma. J Assoc Physicians India. Jul 1984;32(7):579–580.4
Gustafsson PM. A double-blind comparison of the bronchodilatory effect of cumulative doses of salbutamol from Diskus (Accuhaler) and Turbuhaler. Eur J Clin Pharmacol. 2001;57(12):913–914.6-DELIVERY
Gustafsson PM, von Berg A, Jenkins MM. Salmeterol 50 [micro]g twice daily in the treatment of mild-to-moderate asthma in childhood - a comparison of two inhalation devices. An international study group. European Journal of Clinical Research. 1994;5:63–73.6-DELIVERY
Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic air-flow limitation. Effects of airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987;135(5):1069–1074.6
Haahtela T, Vidgren M, Nyberg A, Korhonen P, Laurikainen K, Silvasti M. A novel multiple dose powder inhaler. Salbutamol powder and aerosol give equal bronchodilatation with equal doses. Ann Allergy. 1994;72(2):178–182.6-DELIVERY
Habashy D, Lam LT, Browne GJ. The administration of beta2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey. European Journal of Emergency Medicine. Sep 2003;10(3):219–224.6
Hadjikoumi I, Loader P, Bracken M, Milner AD. Bronchodilator therapy and hyperactivity in preschool children. Arch Dis Child. 2002;86(3):202–203.6
Haider S. Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department. Respir Care. 2001;46:1081.5
Hambleton G, Shinebourne EA. Evaluation of the effects of isoprenaline and salbutamol aerosols on airways obstruction and pulse rates of children with asthma. Arch Dis Child. 1970;45(244):766–768.6
Hananaia NA, Knobil K, Watkins M, Wire P, Yates J, Darken P. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. Chest. 2002.5
Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K. The bronchodilator response to salmeterol is maintained with regular, long- term use in patients with COPD. Pulm Pharmacol Ther. 2005;18(1):19–22.6
Haney, S. and R. J. Hancox (2007). “Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.” Respiratory Research 8: 19.6
Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J. 1999;14(2):283–287.6
Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000;94(8):767–771.6
Hancox RJ, Taylor DR. Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. Biodrugs. 2001;15(1):11–24.5
Handley DA, Morley J, Vaickus L. Levalbuterol hydrochloride. Expert Opin Investig Drugs. Dec 1998;7(12):2027–2041.5-OPINION PIECE
Hannaway PJ. The hazards of non-prescription sales of inhaled metaproterenol. N Engl Reg Allergy Proc. Mar–Apr 1986;7(2):147–149.5
Hansen NC, Andersen PB. Salbutamol powder inhaled from the Diskhaler compared to salbutamol as nebulizer solution in severe chronic airways obstruction. Respir Med. 1995;89(3):175–179.6-POWDER
Harper TB, Stevens A, Clements D, Vandermeer A, Reisner C. Cardiac safety of Salmeterol in 2 to 4 year old subjects with asthma. J Allergy Clin Immun. 2001;107(2):S108.5
Harris R, Rothwell RP. A comparison between aerosol and inhaled powder administration of fenoterol in adult asthmatics. N Z Med J. 1981;94(697):421–422.6-POWDER
Hartley JP, Nogrady SG, Seaton A. Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients. Brit J Dis Chest. 1979;73(3):271–276.6-POWDER
Hartnett BJ, Marlin GE. Comparison of terbutaline and salbutamol aerosols. Aust N Z J Med. 1977;7(1):13–15.4
Hedenstrom H, Wegener T, Boman G, Wahlander L, Melander B. Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma. Allergy. 1992;47(2 Pt 2):158–163.6-LONG VS. SHORT
Hedstrand U. The effect of a new sympathomimetic beta-receptor stimulating drug (terbutaline) on the pulmonary mechanics in bronchial asthma. Scand J Respir Dis. 1970;51(3):188–194.3
Heijerman HG, Dekker FW, Rammeloo RH, Roldaan AC, Sinninghe HE. Similar efficacy of formoterol via turbuhaler and salmeterol via diskhaler in the treatment of asthma. European Respiratory Society. 1999.5
Heimer D, Brami JL, Liberman D, Bark H. Comparison of a references.r2 adrenergic agonist and an anticholinergic agent given by sequential inhalation in patients with severe chronic obstructive pulmonary disease. Isr J Med Sci. 1991;27(6):307–310.6
Hekking PR, Maesen F, Greefhorst A, Prins J, Tan Y, Zweers P. Long- term efficacy of formoterol compared to salbutamol. Lung. 1990;168 Suppl:76–82.6-LONG VS. SHORT
Hellier JP, Baudrimont M, Dussaule JC, Berenbaum F. Reversible selective beta(2)-adrenoceptor agonist-induced myopathy. Rheumatology. Jan 2002;41(1):111–113.5
Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immun. 1992;89(6):1176–1182.6-LONG VS. SHORT
Hermansson BA, Jenkins RJ. A 4-week comparison of salmeterol and terbutaline in adult asthma. Allergy. 1995;50(7):551–558.6-LONG VS. SHORT
Hey AA, Gillies AJ. Fenoterol administered as an inhaled powder. A comparison with salbutamol powder. N Z Med J. 1985;98(772):74–75.5
Higham MA, Sharara AM, Wilson P, Jenkins RJ, Glendenning GA, Ind PW. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma. Thorax. 1997;52(11):975–980.6-LONG VS. SHORT
Hills EA, Davies S, Geary M. Salmefamol and Salbutamol in exercise- induced asthma in children. Brit J Dis Chest. 1976;70(2):78–82.6
Hindle M, Newton DA, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. Chest. 1995;107(3):629–633.6-POWDER
Hockley B, Johnson NM. Fenoterol versus salbutamol nebuliser solution in asthma. Eur J Respir Dis. 1983;128((Pt 2)):543–545.6-DESIGN
Hodzhev B, Kostianev S, Todorov I, Belev G, Kartev S. Individual results of treatment of COPD with low doses of fenoterol compared with treatment with ipratropium bromide. Folia Med. 1999;41(4):46–52.1
Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther. 2003;25(1):285–297.6
Holmes TH. A comparative clinical trial of metaproterenol and isoproterenol as bronchodilator aerosols. Clin Pharmacol Ther. 1968;9(5):615–624.6
Hoskyns EW, Thomson A, Decker E, Hutchins A, Simpson H. Effect of controlled release salbutamol on nocturnal cough in asthma. Arch Dis Child. 1991;66(10):1209–1212.3
Houghton CM, Langley SJ, Singh SD, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol. 2004;58(4):359–366.6-POWDER
Howard LA, Coleman M. A crossover comparison of isoproterenol, metaproterenol and isoetharine by spirometric determinations. Ann Allergy. 1967;25(9):512–519.6
Huhti E. Clinical comparison of terbutaline and isoprenaline administered by inhalation. A double-blind study. Ann Clin Res. 1972;4(3):152–164.6
Huhti E, Poukkula A. Comparison of fenoterol, ipratropium bromide, and their combination in patients with asthma or chronic airflow obstruction. Respiration. 1986;50(SUPPL. 2):298–301.6
Hultquist C, Ahlstrom H, Kjellman NI, Malmqvist LA, Svenonius E, Melin S. A double-blind comparison between a new multidose powder inhaler (Turbuhaler) and metered dose inhaler in children with asthma. Allergy. 1989;44(7):467–470.6-POWDER
Hultqvist C, Ahlstrom H, Kjellman NI, Malmqvist LA, Svenonius E. A comparison between bricanyl turbuhaler and bricanyl dose aerosol (MDI) in children with asthma. Allergy. 1988;43(Suppl 7):5.5
Hung CH, Chu DM, Wang CL, Yang KD. Hypokalemia and salbutamol therapy in asthma. Pediatr Pulmonol. 1999;27(1):27–31.6-DESIGN
Hung Y-F, Yang W, Chang M-L. Supraventricular tachycardia after fenoterol inhalation: report of two cases. Acta Paediatr Taiwan. May–Jun 2003;44(3):165–167.6-DESIGN
Hussein A, Harrie K, Kussau D. The effects of ipratropium bromide and salbutamol on the isolated hyperinflation during symptomfree periods in asthmatic children. Monatsschr Kinderheilkd. 1990;138(3):135–140.1
Hyland ME, Coward G, Upchurch F, Jones KP. Asthma specific quality of life scale in a study of salmeterol hydroxynaphthoate. Brit J Gen Pract. 1991;41(346):214–215.6
Ibe BO, Portugal AM, Raj JU. Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma. International Archives of Allergy & Immunology. 2006;139(3):225–236.6-DESIGN
Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax. 1995;50(1):62–66.6
Ikeda A, Nishimura K, Koyama H, et al. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration. 1999;66(2):119–123.6-POWDER
Imhof E, Elsasser S, Karrer W, Grossenbacher M, Emmons R, Perruchoud AP. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration. 1993;60(2):84–88.6
Ind P, Borszormenyi Nagy G, Pietinalho A, et al. Formoterol 4.5 microgramm used as needed via turbuhaler was as safe and well tolerated as terbutaline 0.5 mg. European Respiratory Society. 1999.5
Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. Eur Respir J. 2002;20(4):859–866.6-LONG VS. SHORT
Jackson L, Stahl E, Holgate ST. Terbutaline via pressurised metered dose inhaled (P-MDI) and Turbuhaler in highly reactive asthmatic patients. Eur Respir J. 1994;7(9):1598–1601.6-POWDER
Jaffe GV, Grimshaw JJ, Cox GA. A comparative trial of atrovent and ventolin in chronic bronchitis. Practitioner. 1980;224(1342):433–436.6
Jagodzinski J, Wozniakowska U. Broncholytic effect of salbutamol, ventolin and berotec aerosols in bronchial asthma. Pneumonologia Polska. 1981;49(10):695–701.1
Janson C, Boe J, Boman G, Mossberg B, Svedmyr N. Bronchodilator intake and plasma levels on admission for severe acute asthma. Eur Respir J. 1992;5(1):80–85.2
Jantikar, A., B. Brashier, et al. (2007). “Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.” Respiratory medicine 101(4): 845–9.2
Jenkins MM, Hilton CJ, de Kock JC, Palmer JB. Exacerbations of asthma in patients on salmeterol. Lancet. 1991;337(8746):913–914.5
Jenkinson SG, Light RW, George RB. Comparison of albuterol and isoproterenol aerosols in bronchial asthma. Ann Allergy. 1977;39(6):423–425.6
Jenne JW. The debate on S-enantiomers of beta-agonists: tempest in a teapot or gathering storm? J Allergy Clin Immun. 1998;102(6 Pt 1):893–895.5
Jenne JW, Chick TW, Strickland RD, Wall FJ. Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation. J Allergy Clin Immun. May 1977;59(5):383–390.3
Jenne JW, Ridley DJ, Marcucci RA, Druz WS, Rook JC. Objective and subjective tremor responses to oral beta 2 agents on first exposure. A comparison of metaproterenol and terbutaline. Am Rev Respir Dis. 1982;126(4):607–610.3
Jindal SK, Kaur SJ. Relative bronchodilatory responsiveness attributable to sympathetic and parasympathetic activity in bronchial asthma. Respiration. 1989;56(1–2):16–21.6
Jindal SK, Malik SK. Clinical experience with terbutaline sulphate and ipratropium bromide in bronchial asthma. Indian J Chest Dis Allied Sci. Jul–Sep 1979;21(3):130–133.6
Jiro M, et al. Evaluation of the Clinical Efficacy of Berotec Tablet (Fenoterol Hydrobromide) in Patients with Bronchial Asthma. Yakuri to Chiryo. 1979;7(12):4129–4150.1
Johnsen CR, Weeke ER. Turbuhaler (R): a new device for dry powder terbutaline inhalation. Allergy. 1988;43(5):392–395.6-POWDER
Johnson AJ, Spiro S, Clarke SW. Metabolic and cardiotoxic effects of salbutamol. Br Med J. Mar 19 1977;1(6063):772–773.5
Jones A. A comparison of fenoterol (Berotec) and salbutamol (Ventolin. Clin Trials. 1981;18(2):98–103.4
Jones K. Salmeterol in the management of paediatric asthma. Respir Med. Oct 1994;88(9):639–643.5
Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet LP, Haukioja A. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Resp Crit Care. 1995;151(1):66–70.6-LONG VS. SHORT
Juniper EF, Svensson K, Mork A-C, Stahl E. Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest. Jan 2004;125(1):93–97.6-LONG VS. SHORT
Kaae R, Agertoft L, Pedersen S, et al. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6–11 years- old than cumulative high doses of inhaled terbutaline. Br J Clin Pharmacol. 2004;58(4):411–418.6-LONG VS. SHORT
Kamburoff PL, Rime FJ. Oral and inhaled salbutamol as a bronchodilator. Brit J Dis Chest. 1970;64(1):46–54.6
Kaplan AE, Stanbrook M, Travers A, Schiebel N, Rowe BH. Non- selective beta agonists versus beta2-agonists for acute asthma. Cochrane Db Syst Rev. 2006;1.5
Kassner, F., R. Hodder, et al. (2004). “A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.” Drugs 64(15): 1671–82.6
Kasuya S, Kawachi H. Fenoterol by metered dose inhaler and delay of steroid therapy. Lancet. Nov 18 1989;2(8673):1215–1216.5
Kawakami Y. A multi-clinic double-blind trial of salbutamol in bronchial asthma. Postgrad Med J. Mar 1971;47:Suppl:71–74.3
Kelly HW. Risk versus benefit considerations for the beta(2)-agonists. Pharmacotherapy. Sep 2006;26(9 Pt 2):164S–174S.5
Kelly HW. What is new with the beta2-agonists: issues in the management of asthma. Ann Pharmacother. May 2005;39(5):931–938.6
Kemp J, Wolfe J, Grady J, et al. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients. Clin Ther. 1998;20(2):270–282.6-LONG VS. SHORT
Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy. 1993;70(4):316–322.6-LONG VS. SHORT
Kemp JP, Furukawa CT, Bronsky EA, et al. Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. J Allergy Clin Immun. 1989;83(3):697–702.6-POWDER
Kemp JP, Hill MR, Vaughan LM, Meltzer EO, Welch MJ, Ostrom NK. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler. Ann Allergy Asthma Immunol. 1997;79(4):322–326.6-POWDER
Kessler F. Clinical trial of metaproterenol aerosol in bronchial asthma. Ann Allergy. 1964;22:588–593.6-DESIGN
Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis. 1991;144(3 Pt 1):622–625.6-LONG VS. SHORT
Ketchell RI, Jensen MW, Spina D, O’Connor BJ. Dose-related effects of formoterol on airway responsiveness to adenosine 5’-monophosphate and histamine. Eur Respir J. 2002;19(4):611–616.6-LONG VS. SHORT
Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease: Comparison with albuterol and ipratropium. Am J Resp Crit Care. 1999;160(3):1028–1030.6-LONG VS. SHORT
Kiviranta K. Fenoterol inhalation powder and aerosol in the treatment of asthma. Allergy. 1985;40(4):305–307.6-POWDER
Klusova EV, Semenovich NI, Polivanov EG, Pashkova TL. Berotek treatment of bronchial asthma in combination with ischemic heart disease. Sov Meditsina. 1979;4:48–51.1
Knopfli, B. H., O. Bar-Or, et al. (2005). “Effect of ipratropium bromide on EIB in children depends on vagal activity.” Medicine & Science in Sports & Exercise 37(3): 354–9.6
Koivikko A. A comparison of the effects of subcutaneous orciprenaline, salbutamol and terbutaline in asthmatic children. Ann Clin Res. 1974;6(2):99–104.3
Konig P. Treatment of severe attacks of asthma in children with nebulized references.r2 adrenergic agents. Ann Allergy. Mar 1978;40(3):185–188.6
Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. Eur J Med Res. 1996;1(10):465–470.6-LONG VS. SHORT
Kruse M, Rosenkranz B, Dobson C, Ayre G, Horowitz A. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Pulm Pharmacol Ther. 2005;18(3):229–234.6-LONG VS. SHORT
Kumar R, Vats HS. Comparative study of inhaled salbutamol, ipratropium bromide in chronic bronchitis. Indian Pract. 2000;53(11):737–739.6
Kunkel G, Metzenauer C, Virnkaes E, O’Keefe E. Comparison of the bronchodilating effects of salbutamol delivered by a novel multiple dose dry powder inhaler or a conventional metered dose inhaler. European Respiratory Society. 1999.5
Kunkel G, Metzenauer P, Burmann U, O’Keefe E. Evaluation of a patient questionnaire assessing the use of a novel multiple dose dry powder inhaler following a 4 week treatment with salbutamol. European Respiratory Society. 1999.5
Kunkel G, Metzenauer P, Virnkaes C, O’Keefe E. Clinical investigation of a 4 week treatment with salbutamol delivered by a multiple dose dry powder inhaler or a conventional metered dose inhaler. European Respiratory Society. 1999.5
Laberge S, Spier S, Drblik SP, Turgeon JP. Comparison of inhaled terbutaline administered by either the Turbuhaler dry powder inhaler or a metered-dose inhaler with spacer in preschool children with asthma. J Pediatr. 1994;124(5 Pt 1):815–817.6-POWDER
LaForce C, Prenner BM, Andriano K, Lavecchia C, Yegen U. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. J Asthma. 2005;42(2):101–106.6-LONG VS. SHORT
LaForce CF, Ellis EF, Kordansky DW, Cocchetto DM, Sharp JT. Use and acceptance of ventolin Rotacaps and the Rotahaler in 1235 asthmatic patients. Clin Ther. Mar–Apr 1993;15(2):321–329.6-DESIGN
Lahdensuo A. Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis. Respiration. 1984;45(1):67–70.4
Lahdensuo A, Muittari A. Bronchodilator effects of a fenoterol metered dose inhaler and fenoterol powder in asthmatics with poor inhaler technique. Eur J Respir Dis. 1986;68(5):332–335.6-POWDER
Lai CK, Chan CH, Ho SS, Hui AC, Lai KN. Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids. Chest. 1995;108(1):36–40.6-LONG VS. SHORT
Laitinen LA, Poppius H, Haahtela T. Comparison of ipratropium bromide and salbutamol in a long-term trial in asthmatic and bronchitic patients in a cold climate. Scand J Respir Dis. 1979;103:163–169.6
Langley PC. The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers. Clin Ther. Jan 1999;21(1):236–253.6-DESIGN
Langton Hewer S, Hobbs J, Connett G, Lenney W. Salmeterol in the prevention of exercise-induced bronchospasm in preschool children. Eur Respir J. 1994;18:451s.5
Larsson, K. (1982). “Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma.” Respiration 43(1): 57–63.6
Latimer KM, Roberts R, Dolovich J, Hargreave FE. Salbutamol: comparison of bronchodilating effect of inhaled powder and aerosol in asthmatic subjects. Can Med Assoc J. 1982;127(9):857–859.6-POWDER
Laursen LC. Clinical efficacy and safety of Turbuhaler as compared to pressurized MDIs-beta 2-agonists. J Aerosol Med. 1994;7(Suppl 1):S59–62.6-POWDER
Lavorini F, Geri P, Luperini M, et al. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. Br J Clin Pharmacol. 2004;58(5):512–520.6-POWDER
Lawford P, Dowd DE, Palmer KN. A comparison of the duration of action of fenoterol and salbutamol in asthma. Curr Med Res Opin. 1981;7(6):349–351.6-SAMPLE SIZE
Leblanc P, Knight A, Kreisman H, Borkhoff CM, Johnston PR. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Am J Resp Crit Care. 1996;154(2 Pt 1):324–328.6-LONG VS. SHORT
Lee DK, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol. 2003;56(5):494–500.3
Lee H, Izquierdo R, Evans HE. Cardiac response to oral and aerosol administration of beta agonists. J Pediatr. 1983;103(4):655–658.6
Lenney W, Milner AD, Hiller EJ. Use of salbutamol powder in childhood asthma. Arch Dis Child. Dec 1978;53(12):958–961.6-POWDER
Lenney W, Pedersen S, Boner AL, Ebbutt A, Jenkins MM. Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr. 1995;154(12):983–990.6-LONG VS. SHORT
Leopold D, McEvoy A. Salbutamol-induced ketoacidosis. Br Med J. Oct 29 1977;2(6095):1152–1153.5
Li JZ, Mei CR. Therapeutic effect of inhaling berotec by oxygen engine on bronchial asthma. Chinese Journal of Contemporary Pediatrics. 2002;4(4):311–312.1
Liljas B, Stadhl E, Pauwels RA. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma. PharmacoEconomics. Aug 1997;12(2 Pt 2):267–277.6-DELIVERY
Lim TK, Ooi S, Lee SK, Manning P. The efficacy of formoterol vs salbutamol in emergency room asthma: a randomized controlled study. European Respiratory Society. 1999.5
Lindgren B, Sears MR, Campbell M, et al. Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain. Int J Clin Prac. 2005;59(1):62–68.6-LONG VS. SHORT
Lipworth B, Tan S, Devlin M, al. e. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med. 1998;104:431–438.6-LONG VS. SHORT
Lipworth BJ, Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immun. 1999;103(1 Pt 1):88–92.6-LONG VS. SHORT
Lipworth BJ, Dempsey OJ, Aziz I. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. Chest. 2000;118(2):321–328.6
Lipworth BJ, Hall IP, Aziz I, Tan KS, Wheatley A. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy. Clin Sci. Mar 1999;96(3):253–259.6-LONG VS. SHORT
Lipworth BJ, Sims EJ, Das SK, Morice AH, O’Connor BJ. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Ann Allergy Asthma Immunol. Sep 2005;95(3):283–290.6-POWDER
Littner MR, Tashkin DP, Calvarese B, Bautista M. Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma. Ann Allergy. 1982;48(1):14–20.6
Lloberes P, Ramis L, Montserrat JM, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 1988;1(6):536–539.6
Lloberes P, Serra J, Montserrat JM, Picado C, Agusti-Vidal A. Bronchodilator effect of Salbutamol, Ipratropium Bromide and a preparation of Fenoterol and Ipratropium Bromide in bronchial asthma. Annals de Medicina. 1989;75(4):91.1
Lodha R, Gupta G, Baruah BP, Nagpal R, Kabra SK. Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial. Indian Pediatr. 2004;41(1):15–20.6-POWDER
Lofdahl CG, Andersson L, Bondesson E, et al. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J. 1997;10(11):2474–2478.6-POWDER
Lofdahl CG, Svedmyr N. Formoterol fumarate, a new beta 2- adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy. 1989;44(4):264–271.6-LONG VS. SHORT
Lotvall J, Lunde H, Svedmyr N. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. Can Respir J. 1998;5(3):191–194.6-LONG VS. SHORT
Lotvall J, Palmqvist M, Arvidsson P, Mellen A, Ventresca P, Ward J. The therapeutic ratio of racemic-salbutamol is equivalent to R-salbutamol in asthmatic patients. European Respiratory Society. 1999.5
Lundback B, Rawlinson DW, Palmer JB. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group. Thorax. 1993;48(2):148–153.6-LONG VS. SHORT
Madsen BW, Tandon MK, Paterson JW. Cross-over study of the efficacy of four betasub 2-sympathomimetic bronchodilator aerosols. Br J Clin Pharmacol. 1979;8(1):75–82.6-SAMPLE SIZE
Maesen F, Smeets J, Mulder J. Double-blind trial of the bronchospasmolytic effect and the side-effects of terbutaline (Bricanyl(TM)) and fenoterol (Berotec(TM)) given by inhalation to patients with bronchial asthma. Tijdschr Genees - J Drug Res. 1980;5(4):706–710.1
Maesen FP, Costongs R, Smeets JJ, Brombacher PJ, Zweers PG. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest. 1991;99(6):1367–1373.6-LONG VS. SHORT
Maesen FP, Costongs R, Smeets SJ, Zweers PG, Goedhart DM. Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest. 1992;101(5):1376–1381.6
Maesen FP, Smeets JJ, Gubbelmans HL, Zweers PG. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest. 1990;97(3):590–594.6-LONG VS. SHORT
Maesen FP, Smeets JJ, Gubbelmans HL, Zweers PG. Formoterol in the treatment of nocturnal asthma. Chest. 1990;98(4):866–870.6-LONG VS. SHORT
Mahajan VK, Tomashefski JF, Huber GL. Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma. Ann Allergy. 1977;39(5):319–324.6
Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115(4):957–965.6
Malmstrom K, Sorva R, Silvasti M. Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma. Pediatr Allergy Immunol. 1999;10(1):66–70.6-DELIVERY
Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis. 1990;142(5):1147–1152.6-LONG VS. SHORT
Malo JL, Ghezzo H, Trudeau C, Cartier A, Morris J. Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in asthmatic subjects. Am Rev Respir Dis. 1989;140(3):817–821.6-SAMPLE SIZE
Malo JL, Ghezzo H, Trudeau C, L’Archeveque J, Cartier A. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immun. 1992;89(2):567–574.6-LONG VS. SHORT
Mapel D, Chen JC, George D, Halbert RJ. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag Care Interface. 2004;17(4):61–66.3
Marlin GE, Berend N, Harrison AC. Combined cholinergic antagonist and beta 2-adrenoceptor agonist bronchodilator therapy by inhalation. Aust N Z J Med. 1979;9(5):511–514.6
Marlin GE, Bush DE, Berend N. Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. Br J Clin Pharmacol. 1978;6(6):547–549.6
Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1995;8(6):267–271.6-LONG VS. SHORT
Mathieu M, Goldman M, Lellouche N, Sartene R. Kinetics of action of salbutamol inhaled from a metered dose inhaler (MDI) and a “Diskhaler”. Eur J Clin Pharmacol. 1992;42(4):435–438.6-POWDER
Matthys H, Behling B. Comparison of Formoterol and Terbutalin on 110 asthmatic children. Pneumologie. 2000;54(SH1):S64.1
Mattila M, Muittari A. The effect of bronchodilator aerosols on the peak expiratory flow rate in asthmatic patients. Acta Med Scand. 1966;180(4):421–427.4
Mazzei JA, Torres J. Comparative randomized blind cross over study between salbutamol and the fenoterol-ipratropium association (IK 6) in patients with bronchial asthma. Prensa Med Argent. 1985;72(10):329–334.1
McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. Respir Med. 1990;84(4):293–295.6-LONG VS. SHORT
McIntosh D. A trial of fenoterol for nocturnal bronchospasm. Practitioner. Nov 1983;227(1385):1757–1764.6-DESIGN
McCrory, D. C. and C. D. Brown (2008). “Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease [Systematic Review].” Cochrane Database of Systematic Reviews.4
McDonald, N. J., A. I. Bara, et al. (2008). “Anticholinergic therapy for chronic asthma in children over two years of age [Systematic Review].” Cochrane Database of Systematic Reviews.6
Mehra S, Bronsky EA, Pfister P. The Aerolizer[TM] dry powder inhaler allows successful administration of formoterol to pediatric and adult patients with varying degrees of asthma. Chest. 2002.5
Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting beta 2-agonist. Ann Pharmacother. Dec 1993;27(12):1478–1487.5
Micheli F, Cersosimo MG, Scorticati MC, Velez M, Gonzalez S. Myoclonus secondary to albuterol (salbutamol) instillation. Neurology. May 23 2000;54(10):2022–2023.5
Middle MV, Terblanche J, Perrin VL, Hertog MG. Bronchodilating effects of salbutamol from a novel inhaler Airmax. Respir Med. 2002;96(7):493–498.6-DELIVERY
Midgren B, Melander B, Persson G. Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest. 1992;101(4):1019–1022.6-LONG VS. SHORT
Milledge JS. Nebulised salbutamol in life-threatening asthma. Br Med J. Jun 16 1979;1(6178):1628.5
Miraglia del Giudice M, Tomasi L, Ferrara M. Bronchodilator effect of aerosol salbutamol in infantile bronchial asthma. Pediatria. 1974;82(1):48–64.1
Molimard M, Bourcereau J, Le Gros V, Bourdeix I. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Respir Med. Jun 2005;99(6):695–702.6-DESIGN
Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir Med. 2001;95(1):64–70.6-LONG VS. SHORT
Moore RH, Khan A, Dickey BF. Long-acting inhaled beta2-agonists in asthma therapy. Chest. Apr 1998;113(4):1095–1108.5
Mortensen J, Groth S, Lange P, Hermansen F. Effect of terbutaline on mucociliary clearance in asthmatic and healthy subjects after inhalation from a pressurised inhaler and a dry powder inhaler. Thorax. 1991;46(11):817–823.6-POWDER
Myers T, Rogers M, Carl JC, Keresmar C, Savidge M. Pediatric emergency department outcomes comparing levalbuterol vs. racemic albuterol. Respir Care. 2001;46(10):1111.5
Nakayama Y. Clinical trial of salbutamol on bronchial asthma in children. Postgrad Med J. Mar 1971;47:Suppl:118–122.3
Nana A, Youngchaiyud P, Charoenratanakul S, et al. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma. 1998;35(8):647–655.3
Nana A, Youngchaiyud P, Maranetra N, et al. Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med. 1998;92(2):167–172.6-POWDER
Narang NK, Meratwal S, Toshniwal GL. Hypokalaemic effect of salbutamol and terbutaline in bronchial asthma. J Assoc Physicians India. Mar 1991;39(3):301–302.5
Nathan RA, Seltzer JM, Kemp JP, et al. Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol. 1995;75(3):243–248.6-LONG VS. SHORT
Negro Alvarez JM, Miralles Lopez JC, Felix Toledo R, et al. Pressurised metered-dose inhalers (MDIs) versus dry powder inhalers devices (DPIs) to rapid-acting inhaled references.r2-agonists for asthma in children. Allergol Immunopathol. Jul-Aug 2002;30(4):245–249.6-POWDER
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, Group SMARTS. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. Jan 2006;129(1):15–26.6
Newhouse MT, Nantel NP, Chambers CB, Pratt B, Parry-Billings M. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest. 1999;115(4):952–956.6-POWDER
Newhouse MT, Patel P, Parry-Billings M. Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler DPI. Eur Respir J. 2003;21(5):816–820.6-POWDER
Newnham DM, Ingram CG, Earnshaw J, Palmer JB, Dhillon DP. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med. 1993;87(6):439–444.6-LONG VS. SHORT
Newnham DM, Wheeldon NM, Lipworth BJ, McDevitt DG. Relative Beta 2 adrenoceptor selectivity of inhaled Fenoterol and Salbutamol. Scott Med J. 1993;38(2):58.5
Nielsen KG, Bisgaard H. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer. Am J Resp Crit Care. 2001;164(2):256–259.6-LONG VS. SHORT
Nightingale JA, Rogers DF, Barnes PJ. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Resp Crit Care. 1999;159(6):1786–1790.6-LONG VS. SHORT
Nix A, Nichol GM, Robson A, Barnes PJ, Chung KF. Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine- induced bronchoconstriction. Br J Clin Pharmacol. 1990;29(3):321–324.6-LONG VS. SHORT
Noppen M, Vincken W. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Respiration. 2000;67(1):112–113.5
O’Callaghan C, Everard ML, Bush A, et al. Salbutamol dry powder inhaler: efficacy, tolerability, and acceptability study. Pediatr Pulmonol. 2002;33(3):189–193.6-POWDER
Ogawa C, Sano Y. Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics. Nippon Rinsho. 1996;54(11):3081–3086.1
Okamoto LJ. Outcomes and humanistic issues related to treatment of acute bronchospasm. Pharmacotherapy. Sep 2006;26(9 Pt 2):175S–180S.5
Olinsky A, Wolfsdorf J. Double-blind trial of a new bronchodilator in asthmatic children. S Afr Med J. 1972;46(20):609–610.3
O’Riordan TG, Mao W, Palmer LB, Chen JJ. Assessing the effects of racemic and single-enantiomer albuterol on airway secretions in long-term intubated patients. Chest. Jan 2006;129(1):124–132.4
Ortiz G, Menendez R. The effects of inhaled albuterol and salmeterol in 2-to 5-year-old asthmatic children as measured by impulse oscillometry. J Asthma. 2002;39(6):531–536.6-LONG VS. SHORT
Osterman K, Stahl E, Kallen A. Bricanyl Turbuhaler in the treatment of asthma: a six week multi-centre study carried out in Sweden, the United Kingdom, Denmark, Norway and Finland. Eur Respir J. 1991;4(2):175–179.6-POWDER
Ostrom NK. Tolerability of short-term, high-dose formoterol in healthy volunteers and patients with asthma. Clin Ther. Nov 2003;25(11):2635–2646.5
Palma Carlos AG, Barbosa MA. Comparison between fenoterol and salbutamol in asthmatic patients. Allergol Immunopathol. 1977;5(3):227–230.6-DESIGN
Palma-Carlos AG, Palma-Carlos GS. Beta-2-agonists of third generation. Allerg Immunol. Apr 1986;18(4):31–32.5
Palmqvist M, Balder B, Lowhagen O, Melander B, Svedmyr N, Wahlander L. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. J Allergy Clin Immun. 1992;89(4):844–849.6-LONG VS. SHORT
Palmqvist M, Ibsen T, Mellen A, Lotvall J. Salmeterol is a partial beta-2-agonist in relation to formoterol in asthmatic patients. European Respiratory Society. 1999.5
Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Resp Crit Care. 1999;160(1):244–249.6
Pansegrouw DF, Weich DJ, Le Roux FP. Fenoterol and asthma deaths. S Afr Med J. Jun 15 1991;79(12):734–735.5
Parker AL. Airway reactivity is a determinant of bronchodilator responsiveness after methacholine-induced bronchoconstriction. J Asthma. Sep 2004;41(6):671–677.6
Parker, A. L. (2004). “Airway reactivity is a determinant of bronchodilator responsiveness after methacholine-induced bronchoconstriction.” Journal of Asthma 41(6): 671–7.6
Paterson IC, Willey RF, Grant IW. Effects of prolonged administration of pirbuterol by mouth in chronic asthma. Br J Clin Pharmacol. 1977;4(3):376–377.3
Patessio A, Podda A, Carone M, Trombetta N, Donner CF. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. Eur Respir J. 1991;4(3):296–300.6-LONG VS. SHORT
Patseli Troger K, Dietzel U, Schmidt EW. Variability of onset and duration of effect of salmeterol and formoterol in patients with moderate and severe stable asthma. European Respiratory Society. 1999.5
Pauwels R. Formoterol--where does it fit in the current guidelines? Respir Med. Aug 2001;95 Suppl B:S30–34.5
Pauwels RA, Hargreave FE, Camus P, Bukoski M, Stahl E. A 1-year comparison of turbuhaler vs pressurized metered-dose inhaler in asthmatic patients. Chest. 1996;110(1):53–57.6-POWDER
Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J. Nov 2003;22(5):787–794.6-LONG VS. SHORT
Pearlman D, Milgrom H, Andriano K, Feldman J, Ziehmer B. Comparison of formoterol (Aerolizer(R)), albuterol (MDI) and placebo in the prevention of exercise-induced bronchospasm in pediatric patients. Chest. 2002;122(SUPPL 4):114S–115S.5
Pearlman DS. Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. Ann Allergy Asthma Immunol. 1995;75(2):180–184.6-LONG VS. SHORT
Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327(20):1420–1425.6-LONG VS. SHORT
Pearlman DS, Liddle R. Controlling asthma symptoms: Salmeterol compared with salbutamol in large-scale multicentre studies. Eur Respir Rev. 1994;4(21):301–305.6-LONG VS. SHORT
Pierson DJ, Hudson LD, Stark K, Hedgecock M. Cardiopulmonary effects of terbutaline and a bronchodilator combination in chronic obstructive pulmonary disease. Chest. 1980;77(2):176–182.3
Pinto Pereira LM, Clement YN, Pinto Pereira SM. Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance. Int J Clin Pharmacol Res. 2002;22(3–4):73–80.6-DELIVERY
Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma. 2003;40(5):505–514.6-LONG VS. SHORT
Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J. 1999;13(5):988–992.6
Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Respir Med. Nov 1998;92(11):1302–1304.6-DESIGN
Quebe-Fehling E, Brambilla R, Bromly CL, Fishwick K, Walters EH, Hendrick DJ. The duration of action of inhaled formoterol dry powder. Br J Clin Pract. 1996;50(8):446–449.6-LONG VS. SHORT
Quezada A, Mallol J, Moreno J, Rodriguez J. Effect of different inhaled bronchodilators on recovery from methacholine-induced bronchoconstriction in asthmatic children. Pediatr Pulmonol. 1999;28(2):125–129.6-DESIGN
Quinn C. The cost effectiveness of levalbuterol versus racemic albuterol. Am J Manag Care. Jul 2004;10(5 Suppl):S153–157.3
Rabe KF, Jorres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis. 1993;147(6 Pt 1):1436–1441.6
Raissy, H. H. (2006). “Exercise induced bronchospasm in children.”
Ramsdale EH, Otis J, Kline PA, Gontovnick LS, Hargreave FE, O’Byrne PM. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. Am Rev Respir Dis. May 1991;143(5 Pt 1):998–1001.6-LONG VS. SHORT
Randell J, Hamalainen KM, Leinonen M, Keski-Karhu J, Silvasti M, Tukiainen H. Salbutamol via Easyhaler(TM) multidose dry powder inhaler produces equivalent relief of histamine-induced bronchoconstriction to salbutamol via pressurised metered-dose inhaler. Clin Drug Invest. 2000;19(5):335–341.6-DELIVERY
Reti, S. (2006). “Ventolin to Salamol—a crossover study in New Zealand.” New Zealand Medical Journal 119(1244): U2276.6
Rhee YK. A comparison of salmeterol with salbutamol inhalation in treatment of mild to moderate asthma. Tuberculosis and Respiratory Diseases. 1997;44(4):815–821.1
Richter B, Bender R, Berger M. Effects of on-demand beta2-agonist inhalation in moderate-to-severe asthma. A randomized controlled trial. J Intern Med. 2000;247(6):657–666.6-DESIGN
Rickard KA. 2003 safety alert - serevent (salmeterol xinafoate). FDAgov. 2003.5
Robertson W, Simkins J, O’Hickey SP, Freeman S, Cayton RM. Does single dose salmeterol affect exercise capacity in asthmatic men? Eur Respir J. 1994;7(11):1978–1984.6-LONG VS. SHORT
Rodrigo, G. J. and J. A. Castro-Rodriguez (2005). “Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis.[see comment][erratum appears in Thorax. 2006 Mar;61(3):274.]” Thorax 60(9): 740–6.6
Rodrigo, G. J. and L. J. Nannini (2006). “Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials.” American Journal of Emergency Medicine 24(2): 217–22.6
Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency tolerability of inhaled formoterol salbutamol healthy subjects and asthmatics. Eur J Clin Pharmacol. 2000;56(5):363–370.6-LONG VS. SHORT
Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol. 2002;58(4):S53–S60.6-LONG VS. SHORT
Rosenborg J, Larsson P, Rott Z, Bocskei C, Poczi M, Juhasz G. Assessment of a relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Eur J Clin Pharmacol. 2002;58(4):S61–S67.6-LONG VS. SHORT
Rosenborg J, Larsson R, Rott Z, Bocskei C, Poczi M, Juhasz G. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med. 2002;96(6):412–417.6-LONG VS. SHORT
Rosenthal RR, Busse WW, Kemp JP, et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest. 1999;116(3):595–602.6-LONG VS. SHORT
Rozov T. Double-blind, randomized, comparative study on the efficacy and tolerability of terbutaline versus fenoterol, in nebulization, in pediatric asthmatic patients. Rev Bras Med. 1994;51(5):591–597.1
Ruffin RE, Latimer KM, Crockett AJ, Blight MM. A comparative bronchodilator study of salbutamol and salbutamol sulphate that were administered by metered-dose inhalers. Med J Aust.150(5):274–275.6
Russo, G. H., C. A. Bellia, et al. (1986). “Exercise-induced asthma (EIA): its prevention with the combined use of ipratropium bromide and fenoterol.” Respiration 50 Suppl 2: 258–61.2
Rutten-van Molken MP, Custers F, van Doorslaer EK, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J. 1995;8(6):888–898.6-LONG VS. SHORT
Sackner MA, Greeneltch N, Silva G, Wanner A. Bronchodilator effects of terbutaline and epinephrine in obstructive lung disease. Clin Pharmacol Ther. Sep 1974;16(3):499–506.6
Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. Jun 2004;125(6):2309–2321.6
Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. May 18 2004;140(10):802–813.6
Sanguinetti, C. M., S. De Luca, et al. (1986). “Evaluation of Duovent in the prevention of exercise-induced asthma.” Respiration 50 Suppl 2: 181–5.6
Sarin S, Shami S, Cheatle T. Salmeterol in nocturnal asthma. Br Med J. Feb 9 1991;302(6772):347–348.5
Schlimmer P. Formoterol Turbuhaler 6 mug vs. Formoterol Aerolizer 12 mug. Atemweg Lungenkrank. 2000;26(5):263–268.1
Schlimmer P. Single-dose comparison of formoterol (Oxis) Turbuhaler 6 mug and formoterol Aerolizer 12 mug in moderate to severe asthma: A randomised, crossover study. Pulm Pharmacol Ther. 2002;15(4):369–374.6-POWDER
Schreck DM. Asthma pathophysiology and evidence-based treatment of severe exacerbations. Am J Health Syst Pharm. May 15 2006;63(10 Suppl 3):S5–13.6
Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. Nov 2005;23(7):842–847.6-DESIGN
Schumann A, Herxheimer H. The bronchodilator action of salbutamol in asthmatics. Postgrad Med J. Mar 1971;47:Suppl:92–99.6
Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy {see comments}. PharmacoEconomics. 1993;4(5):345–352.6-LONG VS. SHORT
Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 2000;94(6):607–611.6-LONG VS. SHORT
Seberova E, Hartman P, Veverka J, et al. Formoterol given by turbuhaler(R) had as rapid an onset of action as salbutamol given by pMDI. Am J Resp Crit Care. 1999;159(SUPPL):A637.5
Selroos O, Ekstrom T. Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation. Pulm Pharmacol Ther. 2002;15(2):175–183.6-LONG VS. SHORT
Sepracor. A double-blind, double-dummy, randomized, placebo- and active-controlle, multicenter, parallel group study of (R,R)-formoterol in the treatment of subjects with chronic obstructive pulmonary disease. ClinicalTrialsgov. 2004.5
Sepracor. Long term safety study of levalbuterol and racemic albuterol in subjects twelve years of age and older with asthma. ClinicalTrialsgov. 2003.5
Sepracor I. A multicenter, open-label, randomized, active-controlled, parallel group chronic safety study of (R,R)-formoterol in the treatment of subjects with chronic obstructive pulmonary disease. ClinicalTrialsgov. 2003.5
Sestini P, Renzoni E, Robinson S, Poole P, Ram FSF. Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Db Syst Rev. 2006;1.6
Shapiro GS, Yegen U, Xiang J, Kottakis J, Della Cioppa G. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin Ther. 2002;24(12):2077–2087.6-LONG VS. SHORT
Sharma TN, Gupta RB, Gupta PR, Purohit SD. Comparison of intravenous aminophylline, salbutamol and terbutaline in acute asthma. Indian J Chest Dis Allied Sci. Jul-Sep 1984;26(3):155–158.3
Sharma TN, Kala D, Gupta PR, Purohit SD, Gupta RB, Sisodia RS. Comparison of subcutaneous salbutamol and terbutaline with adrenaline. Indian J Chest Dis Allied Sci. 1985;27(1):27–30.3
Shepherd GL, Jenkins WJ, Alexander J. Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms. Lancet. 1991;337(8754):1424.5
Shovlin CL, Tam FW. Salbutamol nebuliser and precipitation of critical cardiac ischaemia. Lancet. Nov 17 1990;336(8725):1258.5
Sichletidis L, Daskalopoulou E, Kyriazis G, et al. Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma. J Int Med Res. 1993;21(2):81–88.6-LONG VS. SHORT
Sichletidis L, Daskalopoulou E, Kyriazis G, et al. Comparative effilcacy of salbutamol and salmeterol in exercise-induced asthma. J Int Med Res. 1993;21(2):81–88.6-LONG VS. SHORT
Siddorn JA. A comparison of the effects of salbutamol, fenoterol, and placebo aerosols on airway resistance in asthmatics. Med J Zambia. 1976;10(6):153–156.6-SAMPLE SIZE
Simons FE, Soni NR, Watson WT, Becker AB. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. J Allergy Clin Immun. 1992;90(5):840–846.6-LONG VS. SHORT
Sinclair JD. The response of asthmatics to bronchodilator aerosols. N Z Med J. Aug 1966;65(408):524–527.6
Singh, J. P., R. Singh, et al. (1992). “A comparative study of bronchodilator actions of ipratropium bromide (atrovent) & salbutamol (ventolin) on exercise induced bronchial asthma.” Journal of the Association of Physicians of India 40(8): 545–7.6
Sjosward KN, Hmani M, Davidsson A, Soderkvist P, Schmekel B. Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness. Respir Med. 2004;98(10):990–999.6
Sjosward KN, Josefsson M, Ahlner J, Schmekel B. Preserved bronchial dilatation after salbutamol does not guarantee protection against bronchial hyperresponsiveness. Clin Physiol Funct I. 2003;23(1):14–20.6
Sly RM, Heimlich EM, Ginsburg J, Busser RJ, Strick L. Exercise-induced bronchospasm: evaluation of metaproterenol. Ann Allergy. 1968;26(5):253–258.6
Smucny J, Flynn C, Becker L, Glazier R. Beta2-agonists for acute bronchitis. Cochrane Db Syst Rev. 2006;1.4
Soler M, Joos L, Bolliger CT, Elsasser S, Perruchoud AP. Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. Eur Respir J. 1994;7(11):1973–1977.6-LONG VS. SHORT
Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. Oct 2002;20(4):819–825.6
Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Safety. 2004;27(10):689–715.5
Sovijarvi AR, Reinikainen K, Freudenthal Y, Andersson P, Riska H. Preventive effects of inhaled formoterol and salbutamol on histamine- induced bronchoconstriction--a placebo-controlled study. Respiration. 1992;59(5):279–282.6-LONG VS. SHORT
Spahn J, Covar R, Stempel DA. Asthma: addressing consistency in results from basic science, clinical trials, and observational experience. J Allergy Clin Immun. May 2002;109(5 Suppl):S490–502.5
Stahl E, Postma DS, Svensson K, et al. Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respir Med. 2003;97(9):1061–1066.6-LONG VS. SHORT
Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy. 1995;50(8):657–663.6-LONG VS. SHORT
Stewart BA, Ahrens RC, Carrier S, et al. Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest. 2000;117(3):714–721.6-DELIVERY
Stewart IB, Labreche JM, McKenzie DC. Acute formoterol administration has no ergogenic effect in nonasthmatic athletes. Med Sci Sports Exerc. 2002;34(2):213–217.4
Stratakos G, Kalomenidis J, Routsi C, Papiris S, Roussos C. Transient lactic acidosis as a side effect of inhaled salbutamol. Chest. Jul 2002;122(1):385–386.5
Sussman HS. Continuous eformoterol and beta 2-receptor responsiveness. Br J Clin Pract. Sep 1995;81:16–17.6
Suwanjutha S, Phanichyakarn P, Poonawarat K. Evaluation of terbutaline therapy in asthmatic children. J Med Assoc Thai. Dec 1976;59(12):550–557.3
Svedmyr N, Lofdahl CG, Svedmyr K. The effect of powder aerosol compared to pressurized aerosol. Eur J Respir Dis. 1982;119:81–88.6-POWDER
Svenonius, E., M. Arborelius, Jr., et al. (1988). “Prevention of exercise-induced asthma by drugs inhaled from metered aerosols.” Allergy 43(4): 252–7.6
Sybrecht GW. Inhaled formoterol was an effective and safe treatment in copd patients. European Respiratory Society. 1999.5
Sykes AP, Ayres JG. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma. Respir Med. 1990;84(2):135–138.6-LONG VS. SHORT
Tammivaara R, Aalto E, Lehtonen K, et al. Comparison of a novel salbutamol multidose powder inhaler with a salbutamol metered dose inhaler in patients with asthma. Curr Ther Res. 1997;58(10):734–744.6-POWDER
Tattersfield A, Lofdahl CG, Postma DS, et al. On demand treatment: comparison of formoterol and terbutaline in moderate asthma. Am J Resp Crit Care. 1999;159(SUPPL):A636.5
Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet. 2001;357(9252):257–261.6-LONG VS. SHORT
Taylor DA, Jensen MW, Aikman SL, Harris JG, Barnes PJ, O’Connor BJ. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am J Resp Crit Care. 1997;156(6):1731–1737.6-LONG VS. SHORT
Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta2 adrenoceptor polymorphism. Thorax. 2000;55(9):762–767.6-LONG VS. SHORT
Taylor DR, Hancox RJ, McRae W, et al. The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma. 2000;37(8):691–700.6-DESIGN
Taylor DR, Town GI, Herbison GP, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax. 1998;53(9):744–752.6-LONG VS. SHORT
Taylor IK, O’Shaughnessy KM, Choudry NB, Adachi M, Palmer JB, Fuller RW. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. J Allergy Clin Immun. 1992;89(2):575–583.6-LONG VS. SHORT
Tierce JC, Meller W, Berlow B, Gerth WC. Assessing the cost of albuterol inhalers in the Michigan and California Medicaid Programs: a total cost-of-care approach. Clin Ther. 1989;11(1):53–61.6-DESIGN
Tinkelman DG, Bleecker ER, Ramsdell J, et al. Proventil HFA and ventolin have similar safety profiles during regular use. Chest. 1998;113(2):290–296.6-DELIVERY
Tomac N, Tuncer A, Saraclar Y, Adalioglu G. Efficacy of salmeterol in the treatment of childhood asthma. Acta Paediatr Jpn. 1996;38(5):489–494.6-DESIGN
Tonnesen F, Laursen LC, Evald T, Stahl E, Ibsen TB. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest. 1994;105(3):697–700.6-POWDER
Totterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J. 1998;12(3):573–579.6-LONG VS. SHORT
Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. Jan 2003;123(1):128–135.4
Tukiainen H, Terho EO. Comparison of inhaled salbutamol powder and aerosol in asthmatic patients with low peak expiratory flow level. Eur J Clin Pharmacol. 1985;27(6):645–647.6-POWDER
Tullett, W. M., K. R. Patel, et al. (1982). “Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise- induced asthma.” Thorax 37(10): 737–40.6
Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis. 1990;142(3):571–575.6-LONG VS. SHORT
Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988;43(9):674–678.6-LONG VS. SHORT
Ulrik CS, Backer V, Bach-Mortensen N. Bronchodilating effect of ipratropium bromide inhalation powder and aerosol in children and adolescents with stable bronchial asthma. Allergy. 1992;47(2 Pt 2):133–137.3
Vaessen-Verberne A. Salmeterol in the treatment of children with asthma. Tijdschr Kindergeneeskd. 1998;49.1
Van Arsdel PP, Jr., Schaffrin RM, Rosenblatt J, Sprenkle AC, Altman LC. Evaluation of oral fenoterol in chronic asthmatic patients. Chest. 1978;73(6 Suppl):997–998.3
van As A. Effect of order of administration of Alupent and Atrovent inhalers when used in combination in chronic obstructive pulmonary disease (COPD). Ann Allergy Asthma Immunol. 1995;74(51).5
van der Molen T, Postma DS, Schreurs AJ, Bosveld HE, Sears MR, Meyboom de Jong B. Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma. Qual Life Res. 1997;6(4):353–361.6-DESIGN
van der Woude HJ, Aalbers R. Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists. Eur Respir J. 2001;18(2):269–271.6
van der Woude HJ, Postma DS, Politiek MJ, Winter TH, Aalbers R. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction. Respir Med. 2004;98(9):816–820.6
van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. Thorax. 2001;56(7):529–535.6
Van Ganse E, van der Linden PD, Leufkens HG, Herings RM, Vincken W, Ernst P. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J. Nov 1995;8(11):1856–1860.6-DESIGN
van Noord JA, Smeets JJ, Maesen FP. A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction. Respir Med. 1998;92(12):1346–1351.6-LONG VS. SHORT
van Schayck CP, Bijl-Hofland ID, Cloosterman SGM, Folgering HTM, van der Elshout FJJ, Van Weel C. Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma. Eur Respir J. 2002;19(2):240–245.6-LONG VS. SHORT
van Schayck CP, Cloosterman SG, Bijl-Hofland ID, van den Hoogen H, Folgering HT, van Weel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respir Med. 2002;96(3):155–162.6-LONG VS. SHORT
van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther. 2003;16(3):153–161.6
Venables T. A multicentre study in general practice to compare the efficacy and tolerability of inhaled salmeterol xinafoate and terbutaline in the treatment of asthma. British Journal of Clinical Research. 1992;3:125–136.6-LONG VS. SHORT
Verberne AA, Fuller R. An overview of nine clinical trials of salmeterol in an asthmatic population. Respir Med. May 1998;92(5):777–782.6-LONG VS. SHORT
Verberne AA, Hop WC, Creyghton FB, et al. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. J Allergy Clin Immun. 1996;97(4):938–946.6-LONG VS. SHORT
Vervloet D, Charpin D, Caboche MC, et al. Comparative trial of Maxair Autohaler versus Ventodisks in poorly coordinated asthma patients. Rev Fr Allergol. 1994;34(2):185–190.1
Vichitvejpaisal P, Joshi GP, Kumar S, White PF. Effects of nebulized beta 2-adrenergic agonists on pulmonary mechanics in anesthetized patients with chronic obstructive pulmonary disease. J Med Assoc Thai. 1996;79(12):779–784.4
Vidgren M, Silvasti M, Korhonen P, Kinkelin A, Frischer B, Stern K. Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol. Arzneimittel-Forschung. 1995;45(1):44–47.6-POWDER
Vidgren P, Silvasti M, Vidgren M, Paronen P, Tukiainen H, Lehti H. In vitro inhalation behaviour and therapeutical response of salbutamol particles administered from two metered dose aerosols. Pharmazie. 1991;46(1):41–43.6-DELIVERY
Vilsvik J, Ankerst J, Palmqvist M, et al. Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis. Respir Med. 2001;95(6):484–490.6-LONG VS. SHORT
Vizel AA, Vizel I, Vizel EA. Comparison of acute bronchodilator tests in patients with chronic obstructive lung disease and bronchial asthma. Problemy Tuberkuleza i Boleznei Legkikh. 2005;7:40–44.1
Volcheck GW, Kelkar P, Bartemes KR, Gleich GJ, Kita H. Effects of (R)-and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clinical & Experimental Allergy. Oct 2005;35(10):1341–1346.6
Vollmer M, Schmidt EW, Ulmer WT. Variability of short-term responses to beta2-adrenoceptor agonists in chronic airways obstruction. Pneumologie. 1995;49(11):584–589.1
von Berg A, Berdel D. Efficacy of formoterol metered aerosol in children. Lung. 1990;168 Suppl:90–98.6-LONG VS. SHORT
von Berg A, Berdel D. Formoterol and salbutamol metered aerosols: comparison of a new and an established beta2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma. Pediatr Pulmonol. 1989;7(2):89–93.6-LONG VS. SHORT
Wallin A, Melander B, Rosenhall L, Sandstrom T, Wahlander L. Formoterol, a new long acting beta2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax. 1990;45(4):259–261.6-LONG VS. SHORT
Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax. 1993;48(6):611–614.6-LONG VS. SHORT
Walters, E. H., J. Walters, et al. (2008). “Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment.” Cochrane Database of Systematic Reviews.6
Wang SW, Liu X, Wiener DJ, Sennett C, Bowers BW, Legorreta AP. Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments. Am J Manag Care. Sep 2001;7(9):913–922.6-DESIGN
Wegener T, Hedenstrom H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest. 1992;102(2):535–538.6-LONG VS. SHORT
Weinberger M. Bronchodilation subsensitivity to salbutamol after salmeterol. Lancet. Oct 7 1995;346(8980):968–969.6-LONG VS. SHORT
Weiner AL. Correspondence regarding levalbuterol and racemic albuterol, July 2004 Supplement. Am J Manag Care. Jan 2005;11(1):53; author reply 54.5
Wenzel SE, Lumry W, Manning M, et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol. 1998;80(6):463–470.6-LONG VS. SHORT
Westby, M., M. Benson, et al. (2004). “Anticholinergic agents for chronic asthma in adults.” Cochrane Database of Systematic Reviews(3): CD003269.6
Westby, M., M. Benson, et al. (2008). “Anticholinergic agents for chronic asthma in adults.” Cochrane Database of Systematic Reviews.6
Wiesemann HG, Kroll VM, Volkl KP, Schneider B. Clinical comparative efficacy trial of pirbuterol in the autohaler and salbutamol in a customary metered-dose aerosol in children with asthma aged 6–12 years. Atemweg Lungenkrank. 1991;17(5):170–174.1
Wilcke JT, Iversen ET, Kok-Jensen A. Effect of salmeterol is independent of previously inhaled salbutamol: a clinical controlled study. Lung. 1998;176(2):133–139.6-LONG VS. SHORT
Willaert W, Daenen M, Bomans P, Verleden G, Decramer M. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J. 2002;19(5):928–935.3
Williamson IJ, Reid A, Monie RD, Fennerty AG, Rimmer EM. Generic inhaled salbutamol versus branded salbutamol. A randomised double-blind study. Postgrad Med J. 1997;73(857):156–158.6-DESIGN
Wolfe J, Kreitzer S, Chervinsky P, et al. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2000;84(3):334–340.6-POWDER
Wong AG, O’Shaughnessy AD, Walker CM, Sears MR. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. Eur Respir J. 1997;10(2):330–336.6-LONG VS. SHORT
Woodman K, Pearce N, Beasley R, Burgess C, Crane J. Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study. Clin Pharmacol Ther. May 1992;51(5):566–571.6-DESIGN
Yasuo K, Terumi T, Kazuhiko ITO, et al. Evaluation of Therapeutic Effects of Formoterol, A. BETA.-receptor Stimulating Bronchodilator, on Bronchial Asthma -A Joint Double-blind Single-dose Study at 30 Institutions (Part 1). Rinsho Hyoka. 1984;12(3):647–670.1
Yeung, R., G. M. Nolan, et al. (1980). “Comparison of the effects of inhaled SCH 1000 and fenoterol on exercise-induced bronchospasm in children.” Pediatrics 66(1): 109–14.6
Yoshimi Y, Fujimura M, Yasui M, Kasahara K, Nakao S. Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma. Arerugi. 2004;53(5):502–507.1
Zainudin BM, Biddiscombe M, Tolfree SE, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax. Jun 1990;45(6):469–473.6-POWDER
Zanen P. Relative efficacy of three different inhalers containing salbutamol in patients with asthma. Eur J Clin Pharmacol. 1997;53(3–4):283–286.5
Zehner WJ, Scott JM, Iannolo PM, Ungaro A, Terndrup TE. Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial. Acad Emerg Med. 1995;2(8):686–691.6
Zwi S, Kanarek DJ, McMurdo J, Goldman HI. Clinical trial of salbutamol aerosol in chronic obstructive airways disease. Postgrad Med J. 1971;47(Suppl):112–115.6-DESIGN



Wrong publication type (letter with insufficient information, editorial, non-systematic review, case report, case series < 10 patients)


Wrong study design (placebo-controlled trial, active-controlled trial, sample size < 10 patients, focus on delivery method, dosing range study, LABA vs. SABA)

Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Cover of Drug Class Review: Quick-relief Medications for Asthma
Drug Class Review: Quick-relief Medications for Asthma: Final Report Update 1 [Internet].
Norris SL, McNally TK, Thakurta S.
Portland (OR): Oregon Health & Science University; 2008 Oct.


PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...